-50.4%
BA vs MRNA
+786.4%
-836.7%
-77.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.9% | -2.2% | -0.7% | -2.8% |
| 7D | -9.1% | -12.7% | +3.6% | -8.6% |
| 30D | -18.9% | -20.7% | +1.7% | -18.3% |
| 3M | -27.5% | +46.3% | -73.8% | -28.8% |
| 6M | -29.8% | +305.2% | -335.1% | -36.4% |
| YTD | -28.2% | +561.2% | -589.4% | -37.2% |
| 1Y | -13.1% | +772.1% | -785.2% | -25.3% |
| 3Y | -28.4% | +147.0% | -175.4% | -35.1% |
| 5Y | -27.2% | -26.1% | -1.1% | -33.3% |
| All | -50.4% | +786.4% | -836.7% | -53.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling